NCT02121847View on ClinicalTrials.gov

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 3, 2014

Primary Completion Date

September 23, 2014

Study Completion Date

September 23, 2014

Conditions
Dry Eye Syndromes
Interventions
DRUG

cyclosporine 0.05% ophthalmic emulsion

Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.

DRUG

carboxymethylcellulose-based lubricant eye drops

Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.

Trial Locations (1)

Unknown

Andover

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02121847 - Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy | Biotech Hunter | Biotech Hunter